Acasti Pharma announces corporate name change to Grace Therapeutics

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Oct 25 2024

0mins

Company Name Change: Acasti Pharma is rebranding to Grace Therapeutics, the name of the company that developed GTx-104 before merging with Acasti in 2021. The new trading symbol on Nasdaq will be "GRCE" starting October 28, 2024.
Progress and Future Plans: CEO Prashant Kohli highlighted significant advancements in the clinical development of GTx-104, including full enrollment of the STRIVE-ON trial and plans for a New Drug Application submission to the FDA in early 2025, alongside restructuring efforts to enhance marketability and attractiveness to investors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.